Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 5/20 | 0.59 |
| ▸ | DRD3 | P35462 | 14/20 | 0.58 |
| ▸ | DRD2 | P14416 | 14/20 | 0.56 |
| ▸ | DRD4 | P21917 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13809547 | 0.95 | DRD3 (0.59) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL13809560 | 0.95 | ADRA1A (0.55) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL13809551 | 0.94 | ADRA1A (0.68) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL13809543 | 0.93 | DRD3 (0.60) | ADRA1ADRD3DRD2DRD4 | |
| SCHEMBL4301030 | 0.91 | ADRA1A (0.54) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL13809540 | 0.90 | ADRA1A (0.53) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL13809558 | 0.90 | DRD3 (0.58) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL13809564 | 0.88 | ADRA1A (0.57) | ADRA1ADRD3DRD2DRD4HTR1A | |
| SCHEMBL13809556 | 0.87 | ADRA1A (0.53) | ADRA1ADRD3DRD2 | |
| SCHEMBL13809567 | 0.87 | ADRA1A (0.62) | ADRA1ADRD3DRD2DRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | ADRA1A 313/4885DRD3 1/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.